KR930000499A - 티옥산테논 항종양제 - Google Patents

티옥산테논 항종양제 Download PDF

Info

Publication number
KR930000499A
KR930000499A KR1019920009956A KR920009956A KR930000499A KR 930000499 A KR930000499 A KR 930000499A KR 1019920009956 A KR1019920009956 A KR 1019920009956A KR 920009956 A KR920009956 A KR 920009956A KR 930000499 A KR930000499 A KR 930000499A
Authority
KR
South Korea
Prior art keywords
compound
hydrogen
alkyl
lower alkyl
methyl
Prior art date
Application number
KR1019920009956A
Other languages
English (en)
Other versions
KR100209826B1 (ko
Inventor
챨스 밀러 테오도어
챨스 콜린스 죠세프
챨스 매티스 켄네쓰
필립 웬트랜드 마크
브루노 페르니 로버트
휴즈 코르베트 토마스
Original Assignee
스터링 윈드롭 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스터링 윈드롭 인코포레이티드 filed Critical 스터링 윈드롭 인코포레이티드
Publication of KR930000499A publication Critical patent/KR930000499A/ko
Application granted granted Critical
Publication of KR100209826B1 publication Critical patent/KR100209826B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655363—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a six-membered ring
    • C07F9/655372—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/10—Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
    • C07D335/12—Thioxanthenes
    • C07D335/14—Thioxanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D335/16—Oxygen atoms, e.g. thioxanthones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

내용 없음

Description

티옥산테논 항종양제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 하기 일반식(I)의 화합물, 또는 그의 약학적으로 허용되는 산부가염 또는 용매화물.
    상기식에서, n은 2 또는 3이고, R1및 R2는 독립적으로 저급 알킬이며, Q는 CH2NHR3, CH2N(R4)SO2R7, CH2NHCHO, CH=N-Ar, C(O)NR5R6, CH2N(R4)C(O)R7, CH2N(C2C5)CHO 및 CH2N(R4)P(O) (O-저급 알킬)2)로 이루어진 그룹중에서 선택된 잔기이고, R3은 수소 또는 저급 알킬이며, R4는 수소 또는 저급 알킬이고, R5는 수소, 저급 알킬 또는 Ar이며, R6은 수소 또는 저급 알킬이고, R7은 저급 알킬 또는 Ar이며, R8은 수소, 저급 알킬, 저급 알콕시 또는 할로겐이고, Ar은 페닐, 또는 메틸, 메톡실, 할로겐 또는 니트로로 치환된 페닐이다.
  2. 제1항에 있어서, Q가 CH2NHR3, CH2N(R4)SO2R7, CH2NHCHO, CH=N-Ar 및 C(O)NR5R6로 이루어진 그룹중에서 선택된 잔기이고, R3은 수소 또는 메틸이며, R7이 저급 알킬인 화합물.
  3. 제2항에 있어서, n이 2이고, R1및 R2가 모두 에틸이며, R8이 수소인 화합물.
  4. 제3항에 있어서, Q가 CH2NHR3, CH2N(R4)SO2R7및 CH2NHCHO로 이루어진 그룹중에서 선택된 잔기인 화합물.
  5. 제4항에 있어서, Q가 CH2NHR3인 화합물.
  6. 제5항에 있어서, 1-[[2-(디에틸아미노)에틸]아미노]-4-[(메틸아미노)메틸]티옥산텐-9-온인 화합물.
  7. 제1항에 있어서, Q가 CH2N(R4)SO2R7, CH2N(R4)C(O)R7, CH2N(C2C5)CHO 및 CH2N(R4)P(O) (O-저급 알킬)2로 이루어진 그룹중에서 선택된 잔기인 화합물.
  8. 제7항에 있어서, n이 2이고, R1및 R2가 모두 에틸이며, R8이 수소인 화합물.
  9. 제8항에 있어서, Q가 CH2N(R4)C(O)R7인 화합물.
  10. 제8항에 있어서, Q가 CH2N(R4)SO2R7인 화합물.
  11. 제10항에 있어서, 시-[[1-[[2-(디에틸아미노)에틸]아미노]-9-옥소티옥산텐-4-일]메틸]메탄설폰아미드인 화합물.
  12. 제1항의 화합물 및 약학적으로 허용되는 담체 또는 희석제를 포함하는, 포유동물에서의 종양 또는 암을 치료하기 위한 약학 조성물.
  13. 제6항의 화합물 및 약학적으로 허용되는 담체 또는 희석제를 포함하는, 포유동물에서의 종양 또는 암을 치료하기 위한 약학 조성물.
  14. 제11항의 화합물 및 약학적으로 허용되는 담체 또는 희석제를 포함하는, 포유동물에서의 종양 또는 암을 치료하기 위한 약학 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920009956A 1991-06-10 1992-06-09 티옥산테논 항종양제 KR100209826B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US71317391A 1991-06-10 1991-06-10
US713,173 1991-06-10
US83515992A 1992-02-13 1992-02-13
US835,159 1992-02-13
US835159 1992-02-13

Publications (2)

Publication Number Publication Date
KR930000499A true KR930000499A (ko) 1993-01-15
KR100209826B1 KR100209826B1 (ko) 1999-07-15

Family

ID=27108950

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920009956A KR100209826B1 (ko) 1991-06-10 1992-06-09 티옥산테논 항종양제

Country Status (20)

Country Link
EP (1) EP0518414B1 (ko)
JP (1) JP3045354B2 (ko)
KR (1) KR100209826B1 (ko)
AT (1) ATE106882T1 (ko)
AU (1) AU642596B2 (ko)
CA (1) CA2070120C (ko)
DE (1) DE69200179T2 (ko)
DK (1) DK0518414T3 (ko)
ES (1) ES2055635T3 (ko)
FI (1) FI114024B (ko)
HU (1) HU218655B (ko)
IE (1) IE66828B1 (ko)
IL (1) IL102139A (ko)
MX (1) MX9202753A (ko)
NO (1) NO302364B1 (ko)
NZ (1) NZ242862A (ko)
PH (1) PH30883A (ko)
RU (1) RU2075477C1 (ko)
SG (1) SG50625A1 (ko)
TW (1) TW218015B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5346917A (en) * 1991-06-10 1994-09-13 Sterling Winthrop Inc. Thioxanthenone antitumor agents
US5091410A (en) * 1991-06-10 1992-02-25 Sterling Winthrop Inc. Thioxanthenone antitumor agents
US5665760A (en) * 1995-09-18 1997-09-09 Sanofi Winthrop, Inc. Lyophilized thioxanthenone antitumor agents
EP2175854A4 (en) * 2007-07-31 2012-02-29 Univ North Dakota Res Foundation IMPROVED METHOD FOR THE SYNTHESIS OF SUBSTITUTED FORMYLAMINES AND SUBSTITUTED AMINES
FR2979823B1 (fr) * 2011-09-13 2013-09-27 Pf Medicament Utilisation du 3-(r)-[3-(2-methoxyphenylthio)-2-(s)-methyl-propyl]amino-3,4-dihydro-2h-1,5-benzoxathiepine pour le traitement du cancer et en particulier pour la prevention et/ou le traitement des metastases cancereuses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3745172A (en) * 1970-10-05 1973-07-10 Sterling Drug Inc 1-(di-(lower-alkyl)aminoalkylamino)-9-oxothioxanthenes
US4539412A (en) * 1982-07-08 1985-09-03 Rensselaer Polytechnic Institute 7-Hydroxylucanthone, 7-hydroxhycanthone and their analogs
US5091410A (en) * 1991-06-10 1992-02-25 Sterling Winthrop Inc. Thioxanthenone antitumor agents

Also Published As

Publication number Publication date
IL102139A (en) 1997-03-18
NZ242862A (en) 1993-09-27
NO922273D0 (no) 1992-06-10
HU218655B (hu) 2000-10-28
FI922694A0 (fi) 1992-06-10
IE66828B1 (en) 1996-02-07
NO302364B1 (no) 1998-02-23
DK0518414T3 (da) 1994-08-15
CA2070120A1 (en) 1992-12-11
FI114024B (fi) 2004-07-30
IE921871A1 (en) 1992-12-16
HU9201926D0 (en) 1992-08-28
IL102139A0 (en) 1993-01-14
DE69200179T2 (de) 1995-01-19
JPH05178853A (ja) 1993-07-20
AU1704692A (en) 1992-12-17
MX9202753A (es) 1993-01-01
CA2070120C (en) 2005-11-15
TW218015B (ko) 1993-12-21
ES2055635T3 (es) 1994-08-16
AU642596B2 (en) 1993-10-21
EP0518414A1 (en) 1992-12-16
ATE106882T1 (de) 1994-06-15
KR100209826B1 (ko) 1999-07-15
HUT61992A (en) 1993-03-29
FI922694A (fi) 1992-12-11
SG50625A1 (en) 1998-07-20
RU2075477C1 (ru) 1997-03-20
PH30883A (en) 1997-12-23
JP3045354B2 (ja) 2000-05-29
NO922273L (no) 1992-12-11
EP0518414B1 (en) 1994-06-08
DE69200179D1 (de) 1994-07-14

Similar Documents

Publication Publication Date Title
KR950010888A (ko) 평활근세포 증식 및 재발협착증을 억제하는 방법
KR960007592A (ko) 신규한 피롤로카바졸
TW360652B (en) Acryloyl substituted disstamycin derivatives, process for preparing them, and pharmaceutical composition comprising them
KR910002873A (ko) 티아졸로[5,4-b] 아제핀 화합물
KR930000499A (ko) 티옥산테논 항종양제
KR860008973A (ko) 2-피롤리돈 유도체
HUP0402341A2 (hu) Szubsztituált tiazol-2-ilaminokat tartalmazó készítmények rák kezelésére
KR950032183A (ko) 글루코피라노사이드 벤조티오펜
KR900016178A (ko) 2-치환 n,n'-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물
RU94011565A (ru) Тиоксантеноновые соединения, их использование, противоопухолевая композиция
NO941288L (no) Tioxantenon for bruk som antitumormidler
KR960700710A (ko) 항종양 조성물 및 치료방법(antitumor compositions and methods of treatment)
DK0395527T3 (da) Imidazobenzodiazepiner og deres salte, fremgangsmåde til deres fremstilling, deres anvendelse som lægemidler og præparater med indhold deraf
ATE21908T1 (de) Derivate von 1,4-diaminocyclitol, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
KR940001889A (ko) 과민성 대장 증후군의 치료를 위한 이속사졸 유도체

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]
FPAY Annual fee payment

Payment date: 20050408

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee